Thesis (M.S.)--University of Florida, 2004. / Typescript. Title from title page of source document. Document formatted into pages; contains 52 pages. Includes Vita. Includes bibliographical references.

Thesis (Ph. D.)--West Virginia University, 2007. / Title from document title page. Document formatted into pages; contains viii, 306 p. : ill. (some col.). Vita. Includes abstract. Includes bibliographical references.

Les parasites apicomplexes sont ubiquitaires et ont une forte incidence en médecine humaine et vétérinaire. Certains de ces parasites, comme Plasmodium falciparum, l’agent du paludisme, ou Toxoplasma gondii, l’agent de la toxoplasmose, posent des problèmes de santé publique. Les thérapies existantes montrent parfois une efficacité limitée, une forte toxicité et entraînent des résistances, d’où la nécessité de nouvelles approches plus spécifiques. Dans ce contexte, nous avons développé deux approches d’inhibition des apicomplexes : -la synthèse de biphénylimidazoazines à large spectre efficaces au micromolaire sur cinq parasites apicomplexes différents in vitro. -la synthèse d’imidazo[1,2-b]pyridazines ciblant spécifiquement une protéine kinase (CDPK1) de T. gondii et efficaces au submicromolaire sur le parasite in vitro. Une diminution de plus de 90 % de la charge parasitaire chez la souris et une innocuité à court terme font de ces imidazo[1,2-b]pyridazines de bons candidats thérapeutiques. / Apicomplexan parasites are ubiquitous and have a strong incidence in veterinary and human medicine. Some of them, like Plasmodium falciparum, causing malaria, or Toxoplasma gondii, causing toxoplasmosis, are matter of public health concern. The existing therapies may have limited efficiency, high toxicity, and may lead to resistance, highlighting the necessity of new more specific approaches. In this context, we have developed two approaches to inhibit Apicomplexa: -the synthesis of biphenylimidazoazines with broad-spectrum and efficient at the micromolar range on five different apicomplexan parasites in vitro. -the synthesis of imidazo[1,2-b]pyridazines specifically targeting a kinase protein (CDPK1) of T. gondii and efficient at the submicromolar range on the parasite in vitro. More than 90% diminution of parasite burden in mice and short term safety make these imidazo[1,2-b]pyridazines good therapeutic candidates.

La Protéine Kinase CK2 est une enzyme tétramérique composé d'un dimère de sous-unité régulatrice (β) et de deux sous-unités catalytiques, CK2α et/ou CK2α'. La sous-unité catalytique de CK2 est constitutivement active alors que la sous-unité régulatrice régule seulement la sélection des substrats phosphorylés par CK2. CK2 est une Ser/Thr protéine kinase ubiquitaire impliquée dans le contrôle de nombreuses voies de signalisations. La dérégulation de CK2 promeut le développement des cancers et il a été démontré que CK2 est une cible pertinente dans le traitement des cancers. Notre objectif était de cibler la protéine kinase CK2 de manière indépendante du site actif. Deux séries de composés ont été étudiés : Basé sur un premier hit faiblement actif (CI50 = 30 μM) mais inhibant CK2 de manière non- ATP compétitive, des dérivés comportant le noyau 2-aminothiazole ont été synthétisés et un composé actif (CI50 = 0,6 μM) et efficace in cellulo a été obtenu. Grace à des expériences sur des mutants ponctuels de CK2, des expériences de dichroïsme circulaire, de la STD-RMN et de la modélisation moléculaire, le site de fixation de nos inhibiteurs a été précisément défini à l'interface de la boucle riche en glycine et de l'hélice-αC. Des inhibiteurs de l'interaction α/β ont été étudiés à partir d'un peptide cyclique jusqu'au développement de petites molécules via un screening virtuel. Des études de relations structure-activité ont été réalisé sur la série de composés synthétisées et des tests cellulaires ont été mis en place afin d'évaluer ces composés. Les deux classes de molécules décrites sont des outils intéressants pour comprendre la régulation physiologique de la protéine kinase CK2 et des opportunités prometteuses dans le traitement de certains cancers / The protein kinase CK2 is a tetrameric enzyme composed of a dimer of regulatory subunits (β) and two catalytic subunits, CK2α and/or CK2α’. The catalytic subunit of CK2 is constitutively active, while the regulatory subunit modulates the selectivity toward a subset of substrate proteins. CK2 is a ubiquitous Ser/Thr protein kinase involved in the control of various signaling pathways, and dysregulation of CK2 promotes cancer development. CK2 has been proved to be a valuable target in cancer treatment. Our objective was to target CK2 outside the ATP-pocket. Two independent classes of compounds were studied: Based on a first hit with a low potency (IC50 = 30 μM) but a non-ATP competitive mechanism of action, several 2-aminothiazole derivatives were synthesized to lead to a potent (IC50 = 0.6 μM) and cell efficient allosteric inhibitor of CK2. Using single mutation scanning, CD spectrometry, STD-NMR and docking experiments, the binding site of our compounds was precisely defined outside the ATP-pocket, at the interface of the glycine-rich loop and the αC-helix. Inhibitors of the α/β interaction were studied from a small cyclic peptide to the development of small molecules through Virtual Ligand Screening. Structures Activity Studies were conducted on the synthesized derivatives and cellular based assays to evaluate the α/β inhibitors were set up. The two classes of compounds developed herein are valuable tools to understand the physiological regulation of the protein kinase CK2, and potential new opportunities in cancer treatment / Das Protein Kinase CK2 ist ein tetrameres Enzym, das aus einem Dimer von regulatorischen Untereinheiten (β) und zwei katalytischen Untereinheiten (CK2α und/oder CK2α’) besteht. Die katalytische Untereinheit der CK2 ist konstitutiv aktiv, während die regulatorische Untereinheit die Auswahl einiger der durch CK2 phosphorylierten Substrate steuert. CK2 ist eine ubiquitäre Proteinkinase, die an der Kontrolle zahlreicher Signalwege beteiligt ist. Eine Fehlregulation der CK2 fördert die Tumorenstehung. Es konnte gezeigt werden, dass CK2 eine vielversprechende Zielstruktur für die Entwicklung neuer Therapeutika ist. Unser Ziel war es, neue Hemmstoffe der Proteinkinase CK2 zu entwickeln, die an anderen Stellen als dem aktiven Zentrum angreifen. Zwei Serien von Verbindungen sind untersucht worden: Basierend auf einem ersten schwach aktiven “Hit” (IC50 = 30 μM), der einen nicht-ATPkompetitiven Wirkmechanismus aufwies, wurden einige neue 2-Aminothiazol-Derivate synthetisiert. Dadurch wurden allosterische Inhibitoren mit einer deutlich gesteigerte Potenz (IC50 = 0,6 μM) und einer beachtlichen Zellaktivität erhalten. Mittels eines CK2- Punktmutanten-Screenings, Zirkulardichroismus-Spektrometrie, STD-NMR und molekularer Docking-Simulationen konnte die Bindestelle unserer Hemmstoffe außerhalb der ATPBindetasche, zwischen der Glycin-reichen Schleife und der αC-Helix, lokalisiert werden. Desweiteren wurden niedermolekulare Inhibitoren der α/β-Interaktion entwickelt, ausgehend von einem zyklischen Peptid sowie von Hitverbindungen aus einem virtuellen Screening. Neue Verbindungen wurden synthetisiert und die Struktur- Wirkungsbeziehungen analysiert; zusätzlich wurde ein Zellassay zur Überprüfung des postulierten Wirkmechanismus etabliert. Die beiden entwickelten Verbindungsklassen sind interessante Werkzeuge, um die physiologische Regulation der Proteinkinase CK2 näher zu analysieren; überdies stellen sie Ausgangspunkte für die Entwicklung neuartiger Krebstherapeutika dar

This study demonstrates the presence of protein kinase C activity in both cytosolic and membrane fractions of bovine lens epithelial cells in culture. Protein kinase C activity is similar in normal and hyperglycemic cells. Furthermore, the ability of the enzyme to translocate from the cytosol to the membrane following phorbol ester treatment is unimpeded by hyperglycemic conditions. Moreover, protein kinase C activation had no effect on myoinositol uptake either in normal cells or in cells exposed to hyperglycemic conditions.

Plants are constantly exposed to pathogens and various environmental stresses, such as cold, salinity and drought. Plants normally respond rapidly to these biotic and abiotic stresses. Efficient perception of biotic and abiotic stresses and cell programmed signaling mechanisms for appropriate responses are important for growth and survival of plants. Calcium is an important second messenger in signaling pathways that respond to environmental stresses, pathogen attack as well as hormonal stimuli (For review, see DeFalco et al., 2010; Reddy and Reddy, 2004; Sanders et al., 2002). The transient increase of cytosolic free calcium concentration has been shown in a variety of external signals (Reddy, 2001), which in turn triggers many signal transduction pathways leading to a variety of cellular responses (Bush, 1995). Any calcium mediated signal transduction process involves generation of signal-specific calcium signature in the cytosol (Scrase-Field and Knight, 2003). These changes in cytosolic calcium level or ‘calcium signatures’ are sensed by the specific group of proteins called the ‘calcium sensors’. Different calcium sensors recognize specific calcium signatures and transduce them into downstream effects, including altered protein phosphorylation and gene expression patterns. In plants the protein kinases are a large and differentiated group of calcium sensors. After analyzing 1264 protein kinase sequences, a superfamily of protein kinase called CDPK/SnRK family of protein kinase were defined (Hrabak et al., 2003). CDPK/SnRK family of protein kinases encompasses five subfamilies viz., calcium-dependant protein kinases, (CPKs), calcium/calmodulin dependant protein kinases (CCaMKs), calmodulin-dependant protein kinases (CaMKs), CPKrelated kinases (CRKs), and SnF1 related kinase 3 (SnRK3) and are regulated by calcium directly or indirectly. Among these, in plants, calcium-dependant protein kinases (CPKs) are predominant calcium sensors, which are shown to be involved in myriads of physiological responses. They are Ser/Thr family of protein kinases typically made up of five domains with an Nterminal variable domain followed by catalytic protein kinase domain, an autoinhibitory/ junction domain, a regulatory calmodulin-like domain (CaMLD) and a Cterminal domain of variable length. The CPKs are unique due to the presence of CaMLD which couples the calcium sensor directly to its responder (kinase domain). Although CPKs are highly conserved, there are several features that distinguish different members of the plant CDPK family. In an attempt to investigate the role of a CPK isoform, in the present work we bring out the results and inferences on isolation and characterization of a novel cDNA encoding a calcium-dependant protein kinase isoform ScCPK1 from Swainsonacanescens, a pharmaceutically important Australian herb known to produce an anticancer drug, swainsonine. Initially, we have cloned an 800 bp partial CPK cDNA from S. canescens by reverse transcription polymerase chain reaction (RTPCR) using degenerate oligonucleotide primers designed based on conserved regions of the other known CPKs. A 2.1 kb full length CPK was obtained using 5` and 3` RACE which was designated as ScCPK1. An open reading frame (ORF) of 1659 bp was detected that encodes a protein of 552 amino acids with a calculated molecular mass of 61.8 kDa. Comparison of the deduced amino acid sequence of ScCPK1 with sequences of other CPKs revealed the highest identity (>90%) to Glycine max and Vigna radiate CPKs. As described for other CPKs, ScCPK1 has a long variable domain (88 aa), an auto-inhibitory domain (31 aa) and a C-terminal calmodulin domain (145 aa) containing four EF-hand calcium binding motifs, which is found in many CPKs. Phylogenetic tree analysis showed that ScCPK1 was closely related to StCPK4 , CmCPK1 and CmCPK2. The entire coding region of ScCPK1 was cloned into pRSETA expression vector and expressed as fusion protein in E.coli. The recombinant ScCPK1 protein was purified to homogeneity by NiNTA affinity chromatography. The recombinant purified ScCPK1 was catalytically active in a calcium-dependent manner. The recombinant ScCPK1 phosphorylated itself and histone IIIS as substrate only in the presence of Ca2+. Phosphoaminoacid analyses showed that ScCPK1 phosphorylates serine and threonine residues of histone IIIS and its autophosphorylation also occurs on serine and threonine residues. ScCPK1 has a pH and temperature optima of 7.5 and 37 °C, respectively. It showed high affinity to histone III-S with a Km of 4.8 µM and had a Vmax of 4.700 pmoles of γ32P incorporation/min/mg at saturating substrate concentrations. The ScCPK1 is ~100fold active and showed 10fold higher affinities to histone III-S than CaCPK1 and CaCPK2, CPKs which were characterized from Cicer arietinum previously in our laboratory (Prakash and Jayabaskaran, 2006). From literature it is known that many CPKs are activated or inhibited by metal ions. (PutnamEvans etal., 1990; Anil and Rao, 2001). The influence of Na+ and Mg2+on the in vitro substrate phosphorylation activity of the recombinant ScCPK1 was tested in this work. Addition of NaCl strongly inhibited ScCPK1 activity. The inhibition of substrate phosphorylation activity by salt implies ionic interactions between the positively charged substrate and the enzyme’s active site. The optimum concentration of Mg2+ for ScCPK1 substrate phosphorylation activity was found to be 810 mM, similar to CaCPK1 and CaCPK2 (Prakash and Jayabaskaran, 2006). However, the activity was inhibited above 10 mM Mg2+suggesting the disruption of ionic interactions between the enzyme and the substrate. The kinase and autophosphorylation activities of the recombinant ScCPK1 were calmodulin independent and sensitive to CaM antagonists’ calmidazolium and W7 (N(6aminohexyl)5chloronaphthalene sulphonate). This indicates that the activation was supported by calmodulin-like domain, which is typical of CPK family. Farmer and Choi (1999), showed that DcCPK1 activity was inhibited by polyamines vizspermine and spermidine, and polylysine. We found that substrate phosphorylation activity of ScCPK1 was inhibited by polyLLysine with an IC50 of 8 M but not the polyamines, spermine and spermidine. An interesting aspect that makes CPKs attractive for research is their functional similarity to mammalian PKCs. There are no structural PKC analogues found in plant genomic data. Similar to PKCs, CPKs are regulated by intracellular Ca2+ signals. There is also experimental evidence that some of the CPKs are additionally activated by phospholipids (Farmer and Choi, 1999; Szczegielniak etal., 2000). We investigated the effects of lipid molecules on the activity of ScCPK1. Phosphorylation of histone IIIS by ScCPK1 was stimulated by phosphatidylethanolamine, phosphatidylserine and phosphatidylinositol in the presence of Ca2+, where as lysophosphatidylcholine, phosphatidylcholine and phosphatidic acid did not increase the enzyme activity. Our data that shows interaction of ScCPK1 with phospholipids supports the idea that this protein kinase could be associated with the membrane. The work from Farmer and Choi (1999), with DcCPK1 suggested that some of the PKClike activities observed in plants may be attributed to CPKs. They also demonstrated that DcCPK1 phosphorylated PKC pseudosubstrate peptide and also was sensitive to staurosporine inhibition. However, the protein kinase inhibitor, staurosporine inhibited the substrate phosphorylation activity of ScCPK1 completely with an IC50 value of 700 nM invitro. But PKC inhibitor PMA was less effective, inhibiting the substrate phosphorylation activity of ScCPK1 to a maximum of 50%, but at a very high concentration (200 nM). Our data suggests that ScCPK1 may not have any features attributable to PKC. We investigated subcellular localization of the ScCPK1. To gain a better understanding of the subcellular localization of the ScCPK1, we generated GFP fusion protein of ScCPK1 and transiently expressed it in Agrobacterium-mediated transformed tobacco BY2 cells. Analysis of the GFP expression patterns in transformed tobacco BY2 cells revealed ScCPK1 localization in the plasma membrane of the transformed tobacco BY2 cells despite lacking consensus myristoylation and palmitoylation motifs (as per in silico analyses). Taking together, our data have demonstrated that ScCPK1 is a Ser/Thr protein kinase and its sub-cellular localization studies revealed that it is localized to plasma membrane. We propose that ScCPK1 is a key component of one or more signaling pathways and plays vital roles in plant development, responses to environmental stimuli and/ or in secondary metabolite biosynthetic gene expression. The involvement of the ScCPK1 as a component of signaling pathways warrants further studies.

In plants, calcium is a ubiquitous signaling molecule and changes in cytosolic calcium levels reported in response to various abiotic and biotic stresses like salt stress, drought, pathogen attack and phytohormone signaling. Any calcium- mediated signal transduction process involves the establishment of a signal-specific change in the cytosolic calcium concentration termed as ‗calcium signature‘ which is decoded by the specific group of proteins called ‗calcium sensors‘ (eg: Calmodulin (CaM) and Ca2+ - regulated kinases). Plants have a novel group of kinases designated as Ca2+- dependent protein kinases (CDPK; EC 2.7.1.37). CDPKs are biochemically distinct from other Ca2+- dependent kinases, such as Ca2+- and phospholipid- dependent protein kinases, as they are activated directly by Ca2+-and are independent of CaM. They exist as monomeric serine/threonine protein kinases and consist of four domains namely an amino-terminal variable domain, a kinase domain, an autoinhibitory domain and a calmodulin-like domain (CaM-LD). CDPKs represent a unique class of Ca2+ sensors, having protein kinase as well as CaM-LD in a single polypeptide chain, enabling them to couple the calcium sensor directly to its responder (kinase). In the absence of calcium signature, CDPKs activity is inhibited by the autoinhibitory domain, which acts as a pseudo-substrate of kinase domain and thus blocks the active site of the enzyme. In the presence of calcium signature, CDPKs undergo conformational changes leading to removal of the inhibition. Besides plants, CDPKs are also reported in few protozoans viz Plasmodium falciparam, Paramecium and Taxoplasma. However, CDPKs are not found in the eukaryotic genome of yeast, nematodes, fruitflies and humans. In the current study, we have cloned CDPK1 gene from Cicer arietinum (CaCDPK1) in pRSET-A expression vector and expressed it in Escherichia coli BL21pLysS strain. However, while expressing the recombinant CaCDPK1 in E.coli, most of the recombinant CaCDPK1 protein was expressed as insoluble form. Therefore, we focused our efforts on optimizing the culture conditions for achieving the maximum yield of soluble recombinant CaCDPK1. Expression of the soluble CaCDPK1 was achieved by optimizing the different conditions like IPTG concentrations, temperature and growth time after induction. Maximum amount of soluble expression of recombinant CaCDPK1 was achieved by inducing the bacterial culture with 0.1 mM IPTG at 0.6 OD and growing it further for 4 h at 25°C. As with several other CDPKs, CaCDPK1 was found to get autophosphorylated in a calcium-dependent manner. To find the significance of autophosphorylation, we measured the substrate phosphorylation activity of the native and autophosphorylated CaCDPK1, which revealed that the autophosphorylation enhances the kinase activity of CaCDPK1 by 2-fold. Autophosphorylation was linearly dependant on concentrations of the enzyme suggesting that the autophosphorylation in CaCDPK1 occurs via an intra-molecular mechanism. Further analysis of autophosphorylation shows that autophosphorylation happens before substrate phosphorylation and provides calcium -independent substrate phosphorylation property. It also reduces the lag phase for activation of the enzyme and utilizes both ATP and GTP as phosphor-donor, but ATP is preferred over GTP. Autophosphorylation was found to occur at serine and threonine residues. The MALDI MS/MS analysis of the cold ATP autophosphorylated CaCDPK1 showed Thr- 339, Ser- 357, and Ser- 367 residues could be the potential autophosphorylation sites in CaCDPK1. Phospholipids, the major structural components of membranes, can also have functions in regulating signaling pathways in plants under biotic and abiotic stress conditions. The effects of adding phospholipids on the activity of stress-induced calcium dependent protein kinase (CaCDPK1) from chickpea are reported in this study. Both autophosphorylation as well as phosphorylation of the added substrate were enhanced specifically by phosphatidylcholine and to a lesser extent by phosphatidic acid, but not by phosphatidylethanolamine. Diacylgylerol, the neutral lipid known to activate mammalian PKC, stimulated CaCDPK1 but at higher concentrations. Increase in Vmax of the enzyme activity by these phospholipids significantly decreased the Km indicating that phospholipids enhance the affinity towards its substrate. In the absence of calcium, addition of phospholipids had no effect on the negligible activity of the enzyme. Intrinsic fluorescence intensity of the CaCDPK1 protein was quenched on adding PA and PC. Higher binding affinity was found with PC (K½ = 1.3 nM) when compared to PA (K½ = 56 nM). We also found that the concentration of PA increased in chickpea plants under salt stress. The stimulation by PA and PC suggests regulation of CaCDPK1 by these phospholipids during stress response. In the current study we also investigated CaCDPK1 interactions with calcium ions to address the Ca2+ -induced conformational changes in CaCDPK1 by using circular dichroism (CD), fluorescence spectroscopy and isothermal titration (ITC). Isothermal calorimetric analysis of calcium binding to CaCDPK1 shows a biphasic curve with two Kd of 27 nM and 1.72 µM respectively. The fluorescence measurements showed quenching in fluorescence intensity with a 5 nm red shift. The plot of changes in intensity against calcium concentrations again showed a biphasic curve, indicating that there may be more than one kind of Ca2+ binding sites. 8-anilinonaphthalene-1-sulfonic acid (ANS) binding showed that calcium bound form of CaCDPK1 exposes hydrophobic surfaces which may act as binding sites for other proteins. CD analysis of CaCDPK1 showed that it‘s an alpha helical rich protein and its helical content increases after binding to calcium. Taken all together this study describes the successful heterologous expression of Cicer arietinum CDPK isoform 1 in E.coli. and demonstrates that the autophoshorylation happens via an intra-molecular mechanism and it increases the kinase activity of CaCDPK1 at least by 2-fold. We also report here that CaCDPK1 prefers ATP as phosphodonor over GTP. The present study also shows the activation of CaCDPK1 by PC and PA, but not by PE or diacylglycerol. Both phospholipids were able to bind to CaCDPK1 and increased its Vmax and affinity towards the exogenous substrate, histone III-S. The current study also shows that calicum binding induces conformational changes in CaCDPK1 and the all four EF hand motifs of CaCDPK1 do not function in an equivalent manner.

The overall objective of this thesis was to examine mechanisms involved in the acute regulation of sarcoplasmic reticulum (SR) Ca2+-handling properties by second messenger signaling pathways in skeletal and cardiac muscle. The aim of the first study (Chapter Two) was to characterize changes in the kinetic properties of sarco(endo)-plasmic reticulum Ca2+-ATPase (SERCA) proteins in cardiac and skeletal muscles in response to b-adrenergic, Ca2+-dependent calmodulin kinase II (CaMKII) and protein kinase C (PKC) signaling. The aim of the second study (Chapter Three) was to determine if insulin signaling could acutely regulate SERCA kinetic properties in cardiac and skeletal muscle. The aim of the final study (Chapter Four) was to determine if alterations in plasma glucose, epinephrine and insulin concentrations during exercise are able to influence SR Ca2+-handling properties in contracting human skeletal muscle. Data collected in Chapter Two and Chapter Three were obtained using tissue prepared from a group of 28 male Sprague-Dawley rats (9 weeks of age; mass = 280 ?? 4 g: X ?? S.E). Crude muscle homogenates (11:1 dilution) were prepared from selected hind limb muscles (soleus, SOL; extensor digitorum longus, EDL; the red portion of gastrocnemius, RG; and the white portion of gastrocnemius, WG) and the left ventricle (LV). Enriched SR membrane fractions, prepared from WG and LV, were also analyzed. A spectrophotometric assay was used to measure kinetic properties of SERCA, namely, maximal SERCA activity (Vmax), and Ca2+-sensitivity was characterized by both the Ca50, which is defined as the free Ca2+-concentration needed to elicit 50% Vmax, and the Hill coefficient (nH), which is defined as the relationship between SERCA activity and Ca2+f for 10 to 90% Vmax. The observations made in Chapter Two indicated that b-adrenergic signaling, activated by epinephrine, increased (P<0.05) Ca2+-sensitivity, as shown by a left-shift in Ca50 (i.e. reduced Ca50), without altering Vmax in LV and SOL but had no effect (P<0.05) on EDL, RG, or WG. Further analysis using a combination of cAMP, the PKA activator forskolin, and/or the PKA inhibitor KT5270 indicated that the reduced Ca50 in LV was activated by cAMP- and PKA-signaling mechanisms. However, although the reduced Ca50 in SOL was cAMP-dependent, it was not influenced by a PKA-dependent mechanism. In contrast to the effects of b-adrenergic signaling, CaMKII activation increased SERCA Ca2+-sensitivity, as shown by a left-shift in Ca50 and increased nh, without altering SERCA Vmax in LV but was without effect in any of the skeletal muscles examined. The PKC activator PMA significantly reduced SERCA Ca2+-sensitivity, by inducing a right-shift in Ca50 and decreased nH in the LV and all skeletal muscles examined. PKC activation also reduced Vmax in the fast-twitch skeletal muscles (i.e. EDL, RG and WG), but did not alter Vmax in LV or SOL. The results of Chapter Three indicated that insulin signaling increased SERCA Ca2+-sensitivity, as shown by a left-shift in Ca50 (i.e. reduced Ca50) and an increased nH, without altering SERCA Vmax in crude muscle homogenates prepared from LV, SOL, EDL, RG, and WG. An increase in SERCA Ca2+-sensitivity was also observed in enriched SERCA1a and SERCA2a vesicles when an activated form of the insulin receptor (A-INS-R) was included during biochemical analyses. Co-immunoprecipitation experiments were conducted and indicated that IRS-1 and IRS-2 proteins bind SERCA1a and SERCA2a in an insulin-dependent manner. However, the binding of IRS proteins with SERCA does not appear to alter the structural integrity of the SERCA Ca2+-binding site since no changes in NCD-4 fluorescence were observed in response to insulin or A-INS-R. Moreover, the increase in SERCA Ca2+-sensitivity due to insulin signaling was not associated with changes in the phosphorylation status of phospholamban (PLN) since Ser16 or Thr17 phosphorylation was not altered by insulin or A-INS-R in LV tissue. The data described in Chapter Four was collected from 15 untrained human participants (peak O2 consumption, VO2peak= 3.45 ?? 0.17 L/min) who completed a standardized cycle test (~60% VO2peak) on two occasions during which they were provided either an artificially sweetened placebo (PLAC) or a 6% glucose (GLUC) beverage (~1.00 g CHO per kg body mass). Muscle biopsies were collected from the vastus lateralis at rest, after 30 min and 90 min of exercise and at fatigue in both conditions to allow assessment of metabolic and SR data. Glucose supplementation increased exercise ride time by ~19% (137 ?? 7 min) compared to PLAC (115 ?? 6 min). This performance increase was associated with elevated plasma glucose and insulin concentrations and reduced catecholamine concentrations during GLUC compared to PLAC. Prolonged exercise reduced (p<0.05) SR Ca2+-uptake, Vmax, Phase 1 and Phase 2 Ca2+-release rates during both PLAC and GLUC. However, no differences in SR Ca2+-handling properties were observed between conditions when direct comparisons were made at matched time points between PLAC and GLUC. In summary, the results of the first study (Chapter Two) indicate that b-adrenergic and CaMKII signaling increases SERCA Ca2+-sensitivity in the LV and SOL; while PKC signaling reduces SERCA Ca2+-sensitivity in all tissues. PKC activation also reduces Vmax in the fast-twitch skeletal muscles (i.e. EDL, RG, and WG) but has no effect on Vmax in the LV and SOL. The results of the second study (Chapter Three) indicate that insulin signaling acutely increases the Ca2+-sensitivity of SERCA1a and SERCA2a in all tissues examined, without altering the Vmax. Based on our observations, it appears that the increase in SERCA Ca2+-sensitivity may be regulated, in part, through the interaction of IRS proteins with SERCA1a and SERCA2a. The results of the final study (Chapter Four) indicate that alterations in plasma glucose, epinephrine and insulin concentrations associated with glucose supplementation during exercise, do not alter the time course or magnitude of reductions in SERCA or Ca2+-release channel (CRC) function in working human skeletal muscle. Although glucose supplementation did increase exercise ride time to fatigue in this study, our data does not reveal an association with SR Ca2+-cycling measured in vitro. It is possible that the strength of exercise signal overrides the hormonal influences observed in resting muscles. Additionally, these data do not rule out the possibility that glucose supplementation may influence E-C coupling processes or SR Ca2+-cycling properties in vivo.

Lam Shi Ying Joyce. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2005. / Includes bibliographical references (leaves 107-114). / Abstract in English and Chinese. / Chapter CHAPTER 1 --- GENERAL INTRODUCTION --- p.1-19 / Chapter CHAPTER 2 --- EXPRESSION OF PROTEIN KINASE C (PKC) ISOFORMS IN THE VENTRAL TEMPORAL (VT) AND DORSAL NASAL (DN) RETINAL GROWTH CONES OF MOUSE EMBRYOS / INTRODUCTION --- p.20-22 / MATERIALS AND METHODS --- p.22-24 / RESULTS --- p.24-31 / DISCUSSION --- p.31-37 / FIGURES --- p.38-46 / Chapter CHAPTER 3 --- EFFECTS ON MOUSE NASAL AND TEMPORAL RETINAL NEURITES TO CHONDROITIN SULPHATES (CS) AFTER ALTERATION OF PKC ACTIVITY / INTRODUCTION --- p.47-48 / MATERIALS AND METHODS --- p.49-51 / RESULTS --- p.51-59 / DISCUSSION --- p.60-67 / FIGURES --- p.68-74 / Chapter CHAPTER 4 --- EFFECTS ON AXON ROUTING AFTER ALTERATION OF PKC ACTIVITY ON GUIDANCE OF RETINAL GANGLION CELL AXONS AT THE OPTIC CHIASM OF MOUSE EMBRYOS / INTRODUCTION --- p.75-76 / MATERIALS AND METHODS --- p.77-80 / RESULTS --- p.80-89 / DISCUSSION --- p.89-95 / FIGURES --- p.96-103 / Chapter CHAPTER 5 --- GENERAL CONCLUSION --- p.104-106 / REFERENCES --- p.107-114

This thesis describes the cloning and characterisation of a novel human gene and its protein products, which have been designated SAPK- and Ras-interacting protein (SinRIP). SinRIP shares identity with JC310, a partial human cDNA that was previously identified a candidate Ras-inhibitor (Colicelli et al., 1991, Proc Natl Acad Sci USA 88, p. 2913). In this study, it was shown that SinRIP is a member of an orthologous family of proteins that is conserved from yeast to mammals and contains proteins involved in Ras- and SAPK-mediated signalling pathways. Comparison of this family of proteins showed that human SinRIP contains a potential Ras-binding domain (RBD; residues 279-354), a PH-like domain (PHL; 376-487), and a highly conserved novel region designated the CRIM (134-265). Several other potential targeting sites, such as nuclear localisation signals and target sites for kinases, were identified within the SinRIP sequence. The human SinRIP gene is unusually large (>280 kbp) and is located on chromosome 9 at 9q34. SinRIP mRNA was detected in a wide variety of tissue-types and cell lines by RT-PCR, and the SinRIP sequences in the EST database were derived from an diverse array of tissues, suggesting a widespread or ubiquitous expression. Northern blot analysis revealed the highest levels in skeletal muscle and heart tissue. However, the steady-state levels of SinRIP mRNA vary greatly from cell to cell, and SinRIP expression is likely to be regulated at multiple post-transcriptional levels. It was shown that SinRIP mRNA is likely to be translated inefficiently by the normal cap-scanning mechanism, due to the presence of a GC-rich and structured 5’-UTR, which also contains upstream ORFs. Alternative polyadenylation signals in the SinRIP 3’-UTR can be used, resulting in the expression of short and long SinRIP mRNA isoforms. Several potential A/T-rich regulatory elements were also identified in SinRIP mRNA, which may target specific SinRIP mRNA isoforms for rapid degradation. Importantly, it was shown that SinRIP mRNA is alternatively spliced, resulting in the production of distinct SinRIP protein isoforms. Three isoforms, SinRIP2-4, were definitively identified by RT-PCR and full-length cloning. The SinRIP isoforms contain deletions in conserved regions, and are likely to have biochemical characteristics that are different to full-length SinRIP1. SinRIP2 is C-terminally truncated and lacks the PHL domain and part of the RBD, and relatively high levels of SinRIP2 expression arelikely to occur in kidneys. The RBD is disrupted in SinRIP3, but all other domains are intact, and RT-PCR analyses suggest that SinRIP3 is present in some cells at levels comparable to SinRIP1. A rabbit polyclonal antiserum against SinRIP was generated and detected endogenous SinRIP proteins. Using the anti-SinRIP antibody in immunoblots, multiple SinRIP isoforms were observed in most cell types. SinRIP1 and another endogenous SinRIP protein, likely to be SinRIP3, were detected in most cell lines, and appear to be are the major SinRIP proteins expressed in most cells. The subcellular localisation of both recombinant and endogenous SinRIP proteins was investigated by immunofluorescence assays and biochemical fractionation. Recombinant SinRIP1 protein was found in the cytoplasm and associated with the plasma membrane. In contrast, the SinRIP2 protein was predominantly nuclear, with only low-level cytoplasmic staining observed. The endogenous SinRIP proteins, likely to comprise these and other SinRIP isoforms, were found in both the nucleus and cytoplasm. SinRIP1 interacted with GTP-bound (active) Ras, but not GDP-bound (inactive) Ras, in an in vitro assay, and also co-localised with activated H- and K-Ras in cells. The binding profile observed is typical of Ras-effectors, and SinRIP did not inhibit signalling by the Ras proteins, suggesting that it is not likely to be a Ras-inhibitor. It was also shown that SinRIP1 and SinRIP2 both interact and colocalise with c-Jun NH2- terminal kinase (JNK). Both SinRIP proteins were able to recruit JNK to their respective sub-cellular compartments. These interactions suggest an adaptor role for SinRIP in the Ras and/or JNK pathways. In addition, Sam68 was isolated as a SinRIP-binding protein in a yeast two-hybrid screen. Sam68 was shown to colocalise with SinRIP2 and endogenous SinRIP proteins, but not SinRIP1. Further colocalisation studies showed that endogenous SinRIP proteins localise in nuclear structures that may be associated with pre-mRNA splicing. Likely functions for SinRIP, as indicated by experimental results and studies of the orthologues of SinRIP in other species, are discussed.